Author： Sasaki Takashi
Publisher： Springer Publishing Company
ISSN： 0167-6997
Source： Investigational New Drugs, Vol.30, Iss.2, 2012-04, pp. : 708-713
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Gemcitabine is widely used for the treatment of advanced biliary tract cancer (BTC) as first-line chemotherapy. However, there is no standard chemotherapy for patient with advanced BTC refractory to gemcitabine. We conducted a multicenter phase II study of S-1 monotherapy as second-line chemotherapy for patients with advanced BTC that were refractory to gemcitabine. S-1 was administered orally at a dose of 80 mg/m2 for 28 days, followed by 14 days of rest. This regimen was repeated every 6 weeks. Tumor response was assessed every two cycles using the Response Evaluation Criteria in Solid Tumors version 1.0. Twenty-two patients were enrolled between March 2007 and January 2010, with 14 patients (64%) representing cases of recurrence after surgery. The overall response rate was 22.7%, and the overall disease control rate was 50.0%. The median overall survival time was 13.5 months (95% CI, 7.1-23.1 months) and the median time-to-progression was 5.4 months (95% CI, 2.6-17.2 months). Grade 3/4 toxicities included neutropenia (5%) and anemia (5%). The most common non-hematological toxicities were nausea (27%), anorexia (55%), and pigmentation (32%). In conclusion, S-1 monotherapy is feasible and moderately efficacious second-line chemotherapy for advanced BTC.
Related content
By Brieau Bertrand Dahan Laetitia De Rycke Yann Boussaha Tarek Vasseur Philippe Tougeron David Lecomte Thierry Coriat Romain Bachet Jean-Baptiste Claudez Pierre Zaanan Aziz Soibinet Pauline Desrame Jérome Thirot-Bidault Anne Trouilloud Isabelle Mary Florence Marthey Lysiane Taieb Julien Cacheux Wulfran Lièvre Astrid
Cancer, Vol. 121, Iss. 18, 2015-09 ,pp. :
Access to resources
Recommend
By Lin Nancy Parker Leroy Come Steven Burstein Harold Haldoupis Margaret Ryabin Nicole Gelman Rebecca Winer Eric Shulman Lawrence
Investigational New Drugs, Vol. 25, Iss. 4, 2007-08 ,pp. :